Mr. Rene Goehrum reports

BIOSYENT SCHEDULES FIRST QUARTER EARNINGS RELEASE FOR MAY 15, 2025

BioSyent Inc. will release its financial results for the three months ended March 31, 2025, on Thursday, May 15, 2025, after market hours. A presentation on the company's first quarter 2025 results by Rene Goehrum, BioSyent president and chief executive officer, will also be available on the company's website on the date of release.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol RX, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other health care products that have been developed, are safe and effective, and have a proven record of improving the lives of patients. BioSyent supports the health care professionals who treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the company has 11,254,638 common shares outstanding.

We seek Safe Harbor.